AMLX Quote, Financials, Valuation and Earnings

Esperion Therapeutics has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of -30.85%. Amylyx Pharmaceuticals's return on equity of -109.32% beat Esperion Therapeutics's return on equity of --.

Amylyx Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 111.64%. On the other hand Esperion Therapeutics has an analysts' consensus of $6.63 which suggests that it could grow by 281.11%. Given that Esperion Therapeutics has higher upside potential than Amylyx Pharmaceuticals, analysts believe Esperion Therapeutics is more attractive than Amylyx Pharmaceuticals.

Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Esperion Therapeutics has a beta of 1.042, suggesting its more volatile than the S&P 500 by 4.237%.

Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. Esperion Therapeutics pays out -- of its earnings as a dividend.

Amylyx Pharmaceuticals quarterly revenues are -$665K, which are smaller than Esperion Therapeutics quarterly revenues of $69.1M. Amylyx Pharmaceuticals's net income of -$37.5M is lower than Esperion Therapeutics's net income of -$21.3M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while Esperion Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 2.95x versus 1.01x for Esperion Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of -49.65%. Amylyx Pharmaceuticals's return on equity of -109.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Amylyx Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 111.64%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 37.1%. Given that Amylyx Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Amylyx Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Amylyx Pharmaceuticals quarterly revenues are -$665K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Amylyx Pharmaceuticals's net income of -$37.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 2.95x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of -2357.27%. Amylyx Pharmaceuticals's return on equity of -109.32% beat Palatin Technologies's return on equity of --.

Amylyx Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 111.64%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 829.74%. Given that Palatin Technologies has higher upside potential than Amylyx Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Amylyx Pharmaceuticals.

Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Amylyx Pharmaceuticals quarterly revenues are -$665K, which are smaller than Palatin Technologies quarterly revenues of $350K. Amylyx Pharmaceuticals's net income of -$37.5M is lower than Palatin Technologies's net income of -$2.4M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 2.95x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -17476.92% compared to Amylyx Pharmaceuticals's net margin of --. Amylyx Pharmaceuticals's return on equity of -109.32% beat Theriva Biologics's return on equity of --.

Amylyx Pharmaceuticals has a consensus price target of $8.00, signalling upside risk potential of 111.64%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 398.75%. Given that Theriva Biologics has higher upside potential than Amylyx Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Amylyx Pharmaceuticals.

Amylyx Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.159, suggesting its more volatile than the S&P 500 by 15.945%.

Amylyx Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amylyx Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Amylyx Pharmaceuticals quarterly revenues are -$665K, which are larger than Theriva Biologics quarterly revenues of --. Amylyx Pharmaceuticals's net income of -$37.5M is lower than Theriva Biologics's net income of -$4.4M. Notably, Amylyx Pharmaceuticals's price-to-earnings ratio is 21.03x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amylyx Pharmaceuticals is 2.95x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.